Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 11Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasms 4Sarcoma 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Pancreatic Ductal Adenocarcinoma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1

Interventions

Radiotherapy 22Fluorouracil 20Oxaliplatin 19Leucovorin 14Cisplatin 14Paclitaxel 10Radiation 8Irinotecan 8Docetaxel 7Capecitabine 7Cetuximab 6Carboplatin 6pembrolizumab 5Neoadjuvant Therapy 5Trastuzumab 4Taxes 4Chemotherapy, Adjuvant 4Panitumumab 3Microarray Analysis 3Immunohistochemistry 3Folfox protocol 3Epirubicin 3Biopsy 3tucatinib 2Surgical Procedures, Operative 2Reverse Transcriptase Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma Of Esophagus × spartalizumab × Clear all
NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Novartis

Phase 2 Completed
76 enrolled 14 charts
GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡